Bangor Savings Bank grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 168.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 28,685 shares of the biopharmaceutical company’s stock after acquiring an additional 18,009 shares during the quarter. Bangor Savings Bank’s holdings in Bristol-Myers Squibb were worth $1,369,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc boosted its position in shares of Bristol-Myers Squibb by 1.0% in the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after purchasing an additional 1,229,553 shares during the period. BlackRock Inc. lifted its position in Bristol-Myers Squibb by 0.9% during the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after acquiring an additional 999,193 shares during the period. Dodge & Cox lifted its position in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after acquiring an additional 264,100 shares during the period. Northern Trust Corp lifted its position in Bristol-Myers Squibb by 4.4% during the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after acquiring an additional 954,877 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Bristol-Myers Squibb by 1.1% during the 4th quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after acquiring an additional 180,711 shares during the period. Institutional investors and hedge funds own 74.28% of the company’s stock.

BMY opened at $45.52 on Monday. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $74.38 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. Bristol-Myers Squibb Co has a 12 month low of $44.30 and a 12 month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.85 by $0.09. The business had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the firm earned $0.68 EPS. As a group, research analysts forecast that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 annualized dividend and a dividend yield of 3.60%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

A number of research firms have weighed in on BMY. BMO Capital Markets increased their price objective on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, April 8th. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. Bank of America decreased their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $59.14.

WARNING: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-stake-lifted-by-bangor-savings-bank/2980352.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Trading signals using Bollinger bands

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.